Neurocrine Biosciences, Inc. Stock price

Equities

NBIX

US64125C1099

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
139.4 USD +0.24% Intraday chart for Neurocrine Biosciences, Inc. +0.60% +5.83%
Sales 2024 * 2.21B Sales 2025 * 2.52B Capitalization 13.88B
Net income 2024 * 492M Net income 2025 * 652M EV / Sales 2024 * 5.24 x
Net cash position 2024 * 2.28B Net cash position 2025 * 3.03B EV / Sales 2025 * 4.31 x
P/E ratio 2024 *
29.7 x
P/E ratio 2025 *
22.3 x
Employees 1,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.54%
More Fundamentals * Assessed data
Dynamic Chart
Neurocrine Biosciences Insider Sold Shares Worth $5,576,710, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $420,419, According to a Recent SEC Filing MT
Transcript : Neurocrine Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:15 AM
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $200 From $170, Maintains Outperform Rating MT
Transcript : Neurocrine Biosciences, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 08:40 AM
Transcript : Neurocrine Biosciences, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 11:10 AM
Neurocrine Biosciences Insider Sold Shares Worth $922,632, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $1,085,388, According to a Recent SEC Filing MT
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment CI
Neurocrine Biosciences Insider Sold Shares Worth $1,987,047, According to a Recent SEC Filing MT
UBS Adjusts Price Target on Neurocrine Biosciences to $159 From $128, Maintains Buy Rating MT
Neurocrine Biosciences Insider Sold Shares Worth $376,700, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $313,530, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $290,968, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $359,041, According to a Recent SEC Filing MT
More news
1 day+0.24%
1 week+0.16%
Current month+6.93%
1 month+5.39%
3 months+15.99%
6 months+24.00%
Current year+5.83%
More quotes
1 week
137.66
Extreme 137.66
142.50
1 month
129.15
Extreme 129.15
142.50
Current year
128.00
Extreme 128
143.35
1 year
89.04
Extreme 89.04
143.35
3 years
71.88
Extreme 71.875
143.35
5 years
71.85
Extreme 71.85
143.35
10 years
12.17
Extreme 12.17
143.35
More quotes
Managers TitleAgeSince
Founder 66 91-12-31
Director of Finance/CFO 44 17-10-31
Chief Tech/Sci/R&D Officer 60 21-11-29
Members of the board TitleAgeSince
Director/Board Member 75 99-03-31
Director/Board Member 72 15-09-30
Founder 66 91-12-31
More insiders
Date Price Change Volume
24-03-18 139.4 +0.24% 664,683
24-03-15 139.1 -0.04% 1,739,211
24-03-14 139.2 -1.86% 1,182,246
24-03-13 141.8 +2.95% 1,073,582
24-03-12 137.7 -0.63% 650,983

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering and developing pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligrams (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson's disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. Its pipeline also includes DYSVAL (valbenazine), ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules), ALKINDI/ALKINDI SPRINKLE (hydrocortisone), and EFMODY (hydrocortisone modified-release hard capsules).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
139.4 USD
Average target price
151.4 USD
Spread / Average Target
+8.60%
Consensus
  1. Stock
  2. Equities
  3. Stock Neurocrine Biosciences, Inc. - Nasdaq